Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA

Jazz Pharmaceuticals outlined its U.S. launch plans for Ziihera after FDA approval for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The approval supports near-term commercialization prospects for JAZZ, though the article provides no sales or timing milestones.